Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Rib-X Updates Pipeline Progress

By Drug Discovery Trends Editor | May 11, 2011

Rib-X presented data demonstrating potent activity against multi-drug resistant Gram-negative and Gram-positive bacteria for its clinical candidates, radezolid and delafloxacin, and for its preclinical development program, RX-04 features pipeline candidates at a recent conference.

The company described the efficacy of sample compounds from each of the three families of protein synthesis inhibitors from the RX-04 program when tested in three in vivo models of Gram-negative and Gram-positive infections.  Bacterial burden reduction in all three models was exhibited with at least one compound, and a number of compounds were highly effective in the two Gram-negative infection models.

Rib-X also presented data confirming the novel classes directly impact ribosome function and exert their antibacterial activity by interfering with protein synthesis.
The inhibition of protein synthesis via different mechanisms is a common antibacterial strategy; however, Rib-X’s proprietary knowledge of the ribosome allowed the identification of a site for de novo design that has not been exploited by marketed ribosome inhibitors and is remote from sites of known target-based resistance.

The RX-04 program resulted in multiple series of compounds with activity against Gram-positive and Gram-negative infections resistant to most antimicrobial agents currently used in the clinic.
Delafloxacin was shown to be superior to multiple antibiotics currently used as standards of care for the treatment of MRSA infections, including levofloxacin.

Radezolid demonstrated 2 to 16-fold greater potency compared to torezolid against a collection of Gram-positive bacteria with genetically defined mechanisms of oxazolidinone resistance, including CFR mutants.

Release Date: May 9, 2011
Source: Rib-X 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50